Article
Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.
Scientific reports - 24 Feb 2020
Hettmann Thore, Gillies Stephen D, Kleinschmidt Martin, Piechotta Anke, Makioka Koki, Lemere Cynthia A, Schilling Stephan, Rahfeld Jens-Ulrich, Lues Inge
Abstract excerpt
In clinical trials with early Alzheimer's patients, administration of anti-amyloid antibodies reduced amyloid deposits, suggesting that immunotherapies may be promising disease-modifying interventions against Alzheimer's disease (AD). Specific forms of amyloid beta (Aβ) peptides, for example post-translationally modified Aβ peptides with a pyroglutamate at the N-terminus (pGlu3, pE3), are attractive antibody...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.